Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hoffmann-La Roche
Genmab
Arcus Biosciences, Inc.
Duke University
AstraZeneca
Poseida Therapeutics, Inc.
AstraZeneca
Amgen
AstraZeneca
University of Washington
Novartis
City of Hope Medical Center
NeoTX Therapeutics Ltd.
M.D. Anderson Cancer Center
BicycleTx Limited
BicycleTx Limited
SystImmune Inc.
Masonic Cancer Center, University of Minnesota
Pfizer
TCR2 Therapeutics
Exelixis
Jonsson Comprehensive Cancer Center
Cancer Research UK
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
University of Chicago
Tempus AI
Memorial Sloan Kettering Cancer Center
Carisma Therapeutics Inc
UNICANCER
University of Toronto
Sunnybrook Health Sciences Centre
Shanghai PerHum Therapeutics Co., Ltd.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Baltimore VA Medical Center
Comprehensive Support Project for Oncology Research
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NGM Biopharmaceuticals, Inc